Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis
NCT05535764Phase 1Recruiting
- Sponsor
- University of Utah
- Start
- Aug 2023
- Primary completion
- Jan 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of peginterferon alfa-2a in myelofibrosis (MF), sponsored by University of Utah. Primary endpoint: Dose-Limiting Toxicities at 86 days. Started Aug 2023; status: recruiting.
02
Drugs
peginterferon alfa-2a
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05535764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05535764.